| Literature DB >> 22399121 |
Katharina Hartmann1, Melanie Becker-Putsche, Thomas Bocklitz, Katharina Pachmann, Axel Niendorf, Petra Rösch, Jürgen Popp.
Abstract
Chemotherapies feature a low success rate of about 25%, and therefore, the choice of the most effective cytostatic drug for the individual patient and monitoring the efficiency of an ongoing chemotherapy are important steps towards personalized therapy. Thereby, an objective method able to differentiate between treated and untreated cancer cells would be essential. In this study, we provide molecular insights into Docetaxel-induced effects in MCF-7 cells, as a model system for adenocarcinoma, by means of Raman microspectroscopy combined with powerful chemometric methods. The analysis of the Raman data is divided into two steps. In the first part, the morphology of cell organelles, e.g. the cell nucleus has been visualized by analysing the Raman spectra with k-means cluster analysis and artificial neural networks and compared to the histopathologic gold standard method hematoxylin and eosin staining. This comparison showed that Raman microscopy is capable of displaying the cell morphology; however, this is in contrast to hematoxylin and eosin staining label free and can therefore be applied potentially in vivo. Because Docetaxel is a drug acting within the cell nucleus, Raman spectra originating from the cell nucleus region were further investigated in a next step. Thereby we were able to differentiate treated from untreated MCF-7 cells and to quantify the cell-drug response by utilizing linear discriminant analysis models.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22399121 PMCID: PMC3336052 DOI: 10.1007/s00216-012-5887-9
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Overview of applied DCT treatments
| Batch | Slide number | Exposure time (h) | DCT concentration (nmol/l) |
|---|---|---|---|
| First test series | |||
| 1 | T01 | 24 | 0 |
| T02 | 10 | ||
| T03 | 100 | ||
| 2 | T04 | 48 | 0 |
| T05 | 10 | ||
| T06 | 100 | ||
| 3 | T07 | 24 + 24 | 0 |
| T08 | 10 | ||
| T09 | 100 | ||
| Second test series | |||
| 4 | T10 | 48 | 0 |
| T11 | 2.5 | ||
| T11 | 5 | ||
| T11 | 7.5 | ||
| T12 | 10 | ||
| T13 | 100 | ||
Fig. 1Comparison of a MCF-7 cell stained with H&E (left) and the chemical map of the DNA/RNA distribution based on Raman spectroscopic data (right). The circle marks a structure in the cell with further DNA or RNA content outside the nucleus
Fig. 2Raman images of whole single cells generated by ANN analysis showing the DNA/RNA distribution of untreated (0 nmol/l) and DCT treated (10 nmol/l, 48 h and 100 nmol/l, 48 h) MCF-7 cells. Dark red regions mark high DNA/RNA concentrations and thereby the nucleus position (1st row); results of the k-means cluster analysis (2nd row) and corresponding H&E images of the same cells (3rd row)
Confidence table of the LDA model for separation of control data vs. Raman data containing cell–drug interactions
| Predicted labels | True labels | |
|---|---|---|
| Raman spectra of treated cells | Raman spectra of untreated cells | |
| Raman spectra of treated cells | 10176 | 62 |
| Raman spectra of untreated cells | 77 | 8294 |
Fig. 3Raman mean spectra of DCT treated (red spectrum) and untreated (black spectrum) MCF-7 cells. Significant differences are visible, e.g. the DNA/RNA peak at 785 cm−1 and amide I peak at 1,658 cm−1. These regions are confirmed by the LD scaling vector (green spectrum)
Fig. 4(A) LDA classification of Raman data of various DCT treatments. The histogram of the LD value (scalar product) of all five DCT concentrations is given. With the lowest and highest concentration, the LDA model was trained and all spectra were projected on the LDA model. (B) The dose–effect relationship, as a function of the logarithmically DCT concentration, is visualized. The LD-value can be interpreted as cell response for DCT treatment and shows a sigmoidal trend, which can be utilized for determining the spectral detection limit